21 NOVEMBER 2024

NORTHERN VENTURE TRUST PLC

UNAUDITED HALF-YEARLY FINANCIAL REPORT

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

Northern Venture Trust PLC is a Venture Capital Trust (VCT) whose investment adviser is Mercia Fund Management Limited. The trust was one of the first VCTs launched on the London Stock Exchange in 1995. It invests mainly in unquoted venture capital holdings and aims to provide long-term tax-free returns to shareholders through a combination of dividend yield and capital growth.

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Financial highlights (comparative figures as at 30 September 2023 and 31 March 2024)

  Six months ended

30 September

2024

Six months ended

30 September

2023

Year

ended

31 March

2024

Net assets £119.3m£106.6m£114.8m
Net asset value per share 59.9p61.4p60.3p
Return per share    
Revenue 0.2p0.2p0.6p
Capital 1.0p1.1p1.2p
Total 1.2p1.3p1.8p
Dividend per share declared in respect of the period 1.6p1.6p3.2p
Cumulative return to shareholders since launch    
Net asset value per share 59.9p61.4p60.3p
Dividends paid per share* 193.7p190.5p192.1p
Net asset value plus dividends paid per share 253.6p251.9p252.4p
Mid-market share price at end of period 56.5p56.5p57.5p
Share price discount to net asset value 5.7%8.0%4.6%
Tax-free dividend yield

(based on the net asset value per share)**

 5.2%6.3%5.2%
*        Excluding interim dividend not yet paid.

**        The dividend yield is calculated by dividing the dividends declared in the 12 month period ended on each reference date by the net asset value per share at the start of that period.

Enquiries:

James Sly / Sarah Williams, Mercia Asset Management PLC - 0330 223 1430

Website: www.mercia.co.uk/vcts

HALF-YEARLY MANAGEMENT REPORT TO SHAREHOLDERS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

It is my pleasure to present our interim financial report. Having served on the Board for the past three years, I have witnessed the resilience and evolution of the Company's portfolio and management team as we continue to navigate a dynamic market landscape. Over the past six months, there have been early signs of growth returning in the UK economy, with easing inflationary pressures and some stabilisation in energy prices. While the global political climate remains uncertain and the domestic outlook remains challenging, your Company has continued its long term strategy of investing in promising early-stage businesses, supporting its existing portfolio companies, and generating cash from realisations.

Venture capital investment activity and portfolio update

We are pleased to report an overall increase in the holding value of the unquoted portfolio, the uplifted valuations resulting from our good performers having more than outweighed reductions we felt prudent to make in the valuations of companies that have performed less well.

The portfolio has shown further progress. We have made three new venture capital investments totalling £4.0 million over the six month period and invested £1.9 million in three existing portfolio companies. The new portfolio companies are Ski Zoom (trading as Heidi) (£1.4 million investment), a booking platform for flexible winter mountain breaks, Culture AI (£1.3 million), a cyber security training and monitoring platform, and Promethean Particles (£1.3 million), a developer of carbon capture and storage technologies.

While there has been a cyclical dip in exit confidence among UK venture managers, we nevertheless continued to achieve favourable outcomes from our portfolio investments and the Company received £6.9 million from exits during the period. Notably, we sold the Company's investment in Gentronix, a biotechnology company that provides predictive toxicology solutions. This delivered net proceeds of £6.1 million, representing a 4.5 times return on the original cost. Having supported The Climbing Hangar as it re-established itself after COVID, VCT investment limits prevented us from deploying further capital and we therefore sold NVT's investment for £2.8 million, representing an uplift from the holding value of £2.6 million, equating to 73% of cost.

Results and dividend

The unaudited net asset value (NAV) per share at 30 September 2024 was 59.9 pence (60.3 pence (audited) on 31 March 2024). The total return per share before dividends for the six months ended 30 September 2024 as shown in the income statement was 1.2 pence, compared with 1.3 pence in the corresponding period last year. The performance was driven by a realised gain on disposal of investments of £1.7 million over the last six months, along with an unrealised increase of £1.0 million in the valuation of investments.

Five years ago, we introduced a target dividend yield of 5% of opening NAV, which has been exceeded in each of the years since then. On 23 August 2024 the final dividend of 1.6 pence in respect of the period ending 31 March 2024 was paid to shareholders. After careful consideration, and taking our target yield into account, we have decided to declare an interim dividend of 1.6 pence per share in respect of the year to 31 March 2025. The interim dividend will be paid on 22 January 2025 to shareholders on the register on 20 December 2024.

We continue to operate our dividend investment scheme, which enables shareholders to invest their dividends in new ordinary shares free of dealing costs and with the benefit of the tax reliefs available on new VCT share subscriptions. We have included details of the scheme within the dividend section of our website, which can be found at: www.mercia.co.uk/vcts/nvt/.

Shareholder issues

In April 2024 shares related to the second allotment of the 2023/24 share offer, totalling £20 million, were issued. The Company issued 12,234,307 new ordinary shares, yielding gross subscriptions of £7.8 million.

We continue to observe a sustained demand for long-term growth capital for smaller companies in the UK, and the Investment Adviser has reviewed an increasing number of opportunities. We therefore announced in late September 2024 our intention to fundraise in the current tax year, in conjunction with the other Northern VCTs. This will allow us to further support our existing portfolio and selectively to invest in new early-stage opportunities. We remain grateful for our existing shareholders' continued support. Full details of how to participate in the planned £15 million fundraise will be published in January 2025.

We have maintained our policy of being willing to buy back the Company's shares in the market to maintain liquidity, at a 5% discount to NAV. During the period a total of 4,445,489 shares were purchased by the Company for cancellation, representing around 2.3% of the opening ordinary share capital.

VCT legislation and qualifying status

The Company has continued to meet the stringent and complex qualifying conditions laid down by HM Revenue & Customs for maintaining its approval as a VCT. The Investment Adviser monitors the position closely and reports regularly to the Board. Philip Hare & Associates LLP has continued to act as independent adviser to the Company on VCT taxation matters.

We are pleased to report that the sunset date for VCTs has been extended. The 'Sunset Clause' is a European state aid requirement, introduced when the VCT scheme received state aid approval, that determines the upfront tax relief available to investors in VCTs. Following a final review by the European Union and the issuance of the necessary statutory instrument in September 2024, the Sunset Clause was officially extended from 2025 to 2035. This provides useful certainty for our Company and the investment team.

Board succession

We have previously reported the retirement of previous Chair Simon Constantine, and Richard Green, Chair of the Audit Committee. We would like to reiterate our gratitude to Simon and Richard for their years of dedicated service and significant contributions to the Company.

After almost 10 years of service to the Company, David Mayes has decided not to seek re-election to the Board of Directors at the upcoming Annual General Meeting. We would like to express our gratitude for his invaluable contributions to the Company during his tenure. A process to identify and appoint a successor will be undertaken in the coming months.

We are pleased to report that Brigid Sutcliffe, who joined the board in April 2024, has succeeded Richard as Chair of the Audit Committee.

Additionally, we were delighted to welcome John Milad to the Board as a non-executive director, effective from August 2024. John brings over 25 years' experience as an executive leader, board member, venture capital investor and investment banker focused on the life sciences and medical technology sector.

With these changes, we are confident the Company remains in capable hands. The Board's collective experience and commitment will ensure we continue to act in the best interests of our shareholders.

Outlook

With inflation stabilising and interest rates starting to fall, there are tentative signs of optimism returning to the UK economy. While uncertainties in the run up to the UK budget and the impact of its fiscal measures may still influence market dynamics, we remain confident in the prospects of our portfolio companies. We will continue to work with our Investment Adviser to make the most of the opportunities for value creation as they arise.

On behalf of the Board

Deborah Hudson

Chair

Investment portfolio

As at 30 September 2024 (unaudited)

 Cost

£000

Valuation

£000

% of net assets

by value

Fifteen largest venture capital investments   
Pure Pet Food1,6624,208 3.5%
Project Glow Topco (t/a Currentbody.com)1,6863,854 3.2%
Pimberly2,0603,500 2.9%
Rockar1,8773,448 2.9%
Tutora (t/a Tutorful)3,3053,305 2.8%
Newcells Biotech3,0113,011 2.5%
Grip-UK (t/a The Climbing Hangar)3,8852,821 2.4%
Netacea2,6312,631 2.2%
Ridge Pharma1,4972,585 2.2%
Biological Preparations Group2,3662,222 1.9%
Broker Insights2,0762,118 1.8%
Administrate2,9062,050 1.7%
Forensic Analytics2,0162,016 1.7%
Clarilis1,9721,972 1.7%
LMC Software1,9501,950 1.6%
Fifteen largest venture capital investments34,900 41,691 35.0%
Other venture capital investments50,19842,49435.6%
Total venture capital investments85,098 84,185 70.6%
Net current assets 35,11929.4%
Net assets 119,304 100.0%
Income statement

For the six months ended 30 September 2024 (unaudited)

 Six months

ended 30 September 2024

 Six months

ended 30 September 2023

 Year ended

31 March 2024

Revenue

£000

Capital

£000

Total

£000

 Revenue

£000

Capital

£000

Total

£000

 Revenue

£000

Capital

£000

Total

£000

Gain on disposal of investments-1,7051,705 -834834 -1,2031,203
Movements in fair value of investments-954954 -1,9221,922 -2,4992,499
 -2,6592,659 -2,7562,756 -3,7023,702
            
Dividend and interest income1,020-1,020 873-873 2,220-2,220
Investment management fee(280)(841)(1,121) (260)(780)(1,040) (516)(1,549)(2,065)
Other expenses(320)-(320) (345)-(345) (641)-(641)
            
Return before tax4201,8182,238 2681,9762,244 1,0632,1533,216
Tax on return(101)101- 86(86)- 79(79)-
            
Return after tax3191,9192,238 3541,8902,244 1,1422,0743,216
           ()[\]\\.,;:\s@\"]+)*)|(\".+\"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;return b.test(a)}$(document).ready(function(){if(performance.navigation.type==2){location.reload(true)}$("iframe[data-lazy-src]").each(function(b){$(this).attr("src",$(this).attr("data-lazy-src"))});if($(".owl-article-body-images").length){$(".owl-article-body-images").owlCarousel({items:1,loop:true,center:false,dots:false,autoPlay:true,mouseDrag:false,touchDrag:false,pullDrag:false,nav:true})}var a=$("#display_full_text").val();if(a==0){$.ajax({url:"/ajax/set-article-cookie",type:"POST",data:{cmsArticleId:$("#cms_article_id").val()},dataType:"json",success:function(b){},error:function(b,d,c){}})}$(".read-full-article").on("click",function(d){d.preventDefault();var b=$(this).attr("data-cmsArticleId");var c=$(this).attr("data-productId");var f=$(this).attr("data-href");dataLayer.push({event:"paywall_click",paywall_name:"the_manila_times_premium",paywall_id:"paywall_article_"+b});$.ajax({url:"/ajax/set-article-cookie",type:"POST",data:{cmsArticleId:b,productId:c},dataType:"json",success:function(e){window.location.href=$("#BASE_URL").val()+f},error:function(e,h,g){}})});$(".article-embedded-newsletter-form .close-btn").on("click",function(){$(".article-embedded-newsletter-form").fadeOut(1000)})});$(document).on("click",".article-embedded-newsletter-form .newsletter-button",function(){var b=$(".article-embedded-newsletter-form .newsletter_email").val();var d=$("#ga_user_id").val();var c=$("#ga_user_yob").val();var a=$("#ga_user_gender").val();var e=$("#ga_user_country").val();if(validateEmail(b)){$.ajax({url:"/ajax/sendynewsletter",type:"POST",data:{email:b},success:function(f){$(".article-embedded-newsletter-form .nf-message").html(f);$(".article-embedded-newsletter-form .nf-message").addClass("show");setTimeout(function(){$(".article-embedded-newsletter-form .nf-message").removeClass("show");$(".article-embedded-newsletter-form .nf-message").html("")},6000);dataLayer.push({event:"newsletter_sub",user_id:d,product_name:"newsletter",gender:a,yob:c,country:e})},error:function(f,h,g){}})}else{$(".article-embedded-newsletter-form .nf-message").html("Please enter a valid email address.");$(".article-embedded-newsletter-form .nf-message").addClass("show");setTimeout(function(){$(".article-embedded-newsletter-form .nf-message").removeClass("show");$(".article-embedded-newsletter-form .nf-message").html("")},6000)}});$(document).on("click",".article-embedded-newsletter-form .nf-message",function(){$(this).removeClass("show");$(this).html("")});